The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine : A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis
BACKGROUND: Migraine is a common and disabling primary headache disorder, associated with many medical comorbidities, highly prevalent, with complex treatment and management. Currently, monoclonal antibodies targeting the trigeminal sensory neuropeptide, calcitonin gene-related peptide (CGRP), are available. The aim of this protocol is to provide a review comparing the effects and safety profile of different monoclonal antibodies in migraine patients.
METHODS: The literature search will be performed through the MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), Web of Science and Scopus databases, following the PICO strategy. Real World studies and randomized clinical trials assessing the effect of monoclonal antibodies against CGRP interventions (erenumab, eptinezumab, fremanezumab and galcanezumab) on monthly migraine days (MMD), monthly headache days (MHD), headache impact test (HIT-6) and triptan days of use (TriD) will be included. In Real World studies, the DerSimonian and Laird method will be used to calculate pooled estimates of the mean change difference and in randomized clinical trials, a network meta-analysis will be performed to estimate the comparative effects of different monoclonal antibodies against CGRP.
RESULTS: The findings of this study will be reported in a peer-reviewed journal.
CONCLUSIONS: This study will provide evidence to health professionals on the efficacy and safety of different monoclonal antibodies against CGRP on the outcomes studied.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
International journal of environmental research and public health - 19(2022), 3 vom: 03. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fernández-Bravo-Rodrigo, Jaime [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.02.2022 Date Revised 31.05.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijerph19031753 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336948727 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336948727 | ||
| 003 | DE-627 | ||
| 005 | 20231225233314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijerph19031753 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM336948727 | ||
| 035 | |a (NLM)35162776 | ||
| 035 | |a (PII)1753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fernández-Bravo-Rodrigo, Jaime |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine |b A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Migraine is a common and disabling primary headache disorder, associated with many medical comorbidities, highly prevalent, with complex treatment and management. Currently, monoclonal antibodies targeting the trigeminal sensory neuropeptide, calcitonin gene-related peptide (CGRP), are available. The aim of this protocol is to provide a review comparing the effects and safety profile of different monoclonal antibodies in migraine patients | ||
| 520 | |a METHODS: The literature search will be performed through the MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), Web of Science and Scopus databases, following the PICO strategy. Real World studies and randomized clinical trials assessing the effect of monoclonal antibodies against CGRP interventions (erenumab, eptinezumab, fremanezumab and galcanezumab) on monthly migraine days (MMD), monthly headache days (MHD), headache impact test (HIT-6) and triptan days of use (TriD) will be included. In Real World studies, the DerSimonian and Laird method will be used to calculate pooled estimates of the mean change difference and in randomized clinical trials, a network meta-analysis will be performed to estimate the comparative effects of different monoclonal antibodies against CGRP | ||
| 520 | |a RESULTS: The findings of this study will be reported in a peer-reviewed journal | ||
| 520 | |a CONCLUSIONS: This study will provide evidence to health professionals on the efficacy and safety of different monoclonal antibodies against CGRP on the outcomes studied | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a calcitonin gene-related peptide (CGRP) | |
| 650 | 4 | |a eptinezumab | |
| 650 | 4 | |a erenumab | |
| 650 | 4 | |a fremanezumab | |
| 650 | 4 | |a galcanezumab | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a migraine prevention | |
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 4 | |a protocol | |
| 650 | 4 | |a review | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 700 | 1 | |a Pascual-Morena, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Flor-García, Amparo |e verfasserin |4 aut | |
| 700 | 1 | |a Saz-Lara, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Sequí-Dominguez, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez-Bueno, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Barreda-Hernández, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Cavero-Redondo, Iván |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of environmental research and public health |d 2004 |g 19(2022), 3 vom: 03. Feb. |w (DE-627)NLM162777434 |x 1660-4601 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:3 |g day:03 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijerph19031753 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 3 |b 03 |c 02 | ||